{"id":45839,"date":"2022-07-06T02:01:33","date_gmt":"2022-07-06T00:01:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/"},"modified":"2022-07-06T02:01:33","modified_gmt":"2022-07-06T00:01:33","slug":"touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/","title":{"rendered":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<strong><i>Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer\u2019s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies<\/i><\/strong>\n<\/li>\n<li>\n<strong><i>Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization<\/i><\/strong>\n<\/li>\n<li>\n<strong><i>Access to dbDNA patent rights enables Pfizer\u2019s rapid production of DNA template as starting materials for mRNA-based vaccines and other therapeutics<\/i><\/strong>\n<\/li>\n<\/ul>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.touchlight.com%2F&amp;esheet=52771071&amp;newsitemid=20220705005396&amp;lan=en-US&amp;anchor=Touchlight&amp;index=1&amp;md5=0ae6bd33cfeee3fd6dff86e9d46555c5\" rel=\"nofollow noopener\" shape=\"rect\">Touchlight<\/a>, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer. Under the license agreement, Pfizer gains rights to Touchlight\u2019s enzymatic doggybone DNA (dbDNA\u2122) patent portfolio for worldwide use in Pfizer\u2019s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies. Touchlight will receive an <strong>upfront payment, as well as clinical and commercial milestone payments and royalties upon commercialisation.<\/strong>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/5\/Touchlight_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg\"><\/a><\/p>\n<p>\nTouchlight\u2019s patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint. The technology can manufacture genes &gt;20kb and accommodate sequences typically unstable as plasmid DNA in <i>E. coli, <\/i>such as those found in viral vector and mRNA production. In addition to mRNA vaccines, it is ideally suited for the development of DNA vaccines, advanced therapies, and more.\n<\/p>\n<p>\n<b>Jonny Ohlson, Founder and Executive Chair, Touchlight, commented<\/b>: \u201c<i>We are delighted to establish this agreement with Pfizer to license our mRNA manufacturing platform. This agreement is an example of our technology\u2019s potential to enable companies across the genetic medicine sector to simplify and accelerate DNA manufacturing through the clinic and towards commercialisation.\u201d<\/i>\n<\/p>\n<p>\nFinancial terms are not disclosed.\n<\/p>\n<p>\n<b>About Touchlight<\/b>\n<\/p>\n<p>\nTouchlight is a privately-owned biotechnology company based in London, U.K., focused on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as \u201cdoggybone\u201d or dbDNA\u2122. dbDNA\u2122 is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight\u2019s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.\n<\/p>\n<p>\nLearn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.touchlight.com&amp;esheet=52771071&amp;newsitemid=20220705005396&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.touchlight.com&amp;index=2&amp;md5=faafd9674a1cf16d3377a6fb2ebf247b\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.touchlight.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>At Touchlight:<\/b><br \/>Jonny Ohlson, Executive Chairman<br \/>\n<br \/>Karen Fallen, CEO, Touchlight DNA Services<br \/>\n<br \/>Robin Bodicoat, Head of Marketing<br \/>\n<br \/><b>E<\/b>: <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x69;&#110;fo&#x40;&#x74;&#111;&#117;c&#x68;&#x6c;&#x69;&#103;ht&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#102;&#x6f;&#64;&#x74;o&#117;&#x63;&#104;&#x6c;&#105;&#x67;h&#x74;&#46;&#99;&#x6f;&#109;<\/a><br \/><b>T<\/b>: +44 20 8481 9200<\/p>\n<p><b>At Instinctif Partners:<\/b><br \/>Agnes Stephens \/ Jonjo Cordey<br \/>\n<br \/><b>E<\/b>: <a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#x3a;&#116;&#x6f;&#x75;&#99;&#x68;&#x6c;i&#x67;&#x68;t&#x40;&#105;n&#x73;&#116;i&#x6e;&#99;t&#x69;&#102;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#116;&#x6f;u&#99;&#x68;l&#105;&#x67;h&#116;&#x40;i&#110;&#x73;&#116;&#x69;&#x6e;&#99;&#x74;&#x69;&#102;&#x2e;c&#111;&#x6d;<\/a><br \/><b>T<\/b>: +44 20 7457 2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer\u2019s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer\u2019s rapid production of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45839","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer\u2019s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer\u2019s rapid production of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T00:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies\",\"datePublished\":\"2022-07-06T00:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/\"},\"wordCount\":474,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005396\\\/en\\\/1504426\\\/21\\\/Touchlight_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/\",\"name\":\"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005396\\\/en\\\/1504426\\\/21\\\/Touchlight_logo.jpg\",\"datePublished\":\"2022-07-06T00:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005396\\\/en\\\/1504426\\\/21\\\/Touchlight_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005396\\\/en\\\/1504426\\\/21\\\/Touchlight_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend","og_description":"Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer\u2019s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer\u2019s rapid production of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T00:01:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies","datePublished":"2022-07-06T00:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/"},"wordCount":474,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/","url":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/","name":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg","datePublished":"2022-07-06T00:01:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220705005396\/en\/1504426\/21\/Touchlight_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/touchlight-signs-patent-license-agreement-with-pfizer-for-the-use-of-dbdna-for-the-manufacture-of-mrna-based-vaccines-therapeutics-and-gene-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45839"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45839\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}